Company intelligence

CHRS

Coherus BioSciences, Inc. · NASDAQ · Healthcare

Price$1.36-1.09% · −$0.02

Market cap209.35MEquity value

P / E-1.2Trailing ratio

Volume146.03KLatest session

Market data

CHRS price chart

TradingView

Related signals

1 min delayed

Browse public CHRS signals with their source context and measured market impact. Open any signal for its permanent analysis page.

CHRSDec 3, 2024-17.99% since signal

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Coherus divests Udenyca for up to $558.4 million. Proceeds will repay $230 million in convertible notes. Coherus aims to focus on its immuno-oncology portfolio. Phase 2 trials for new cancer treatments begin in late 2024. CHRS stock rose 41.6% following the announcement.

View signal analysis

Research